İlaç Dirençliliğinde Wnt/Β-Katenin Sinyalizasyonu ve Gstp1 Arasındaki Metabolik Etkileşim

Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6(3):1769–1792. doi:10.3390/cancers6031769

Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726. doi:10.1038/nrc3599

Mansoori B, Mohammadi A, Davudian S, et al. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339–348. doi:10.15171/apb.2017.041

Lei ZN, Tian Q, Teng QX, et al. Understanding and targeting resistance mechanisms in cancer. MedComm (2020). 2023;4(3):e265. doi:10.1002/mco2.265

Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309. doi:10.1038/s41586-019-1730-1

Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357(6348):eaal2380. doi:10.1126/science.aal2380

Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141–160. doi:10.20517/cdr.2019.10

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi:10.1038/s41580-018-0080-4

Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016. Cell. 2016;166(1):21–45. doi:10.1016/j.cell.2016.06.028

McCoach CE, Bivona TG. Engineering multidimensional evolutionary forces to combat cancer. Cancer Discov. 2019;9(5):587–604. doi:10.1158/2159-8290.CD-18-1196

Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043. doi:10.18632/oncotarget.16723

Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012;2(3):214–226. doi:10.1158/2159-8290.CD-12-0012

Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–692. doi:10.1038/nbt.2284

Fitzgerald JB, Schoeberl B, Nielsen UB, et al. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol. 2006;2(9):458–466. doi:10.1038/nchembio817

Yoo H, Kim Y, Kim J, et al. Overcoming cancer drug resistance with nanoparticle strategies for key protein inhibition. Molecules. 2024;29(17):3994. doi:10.3390/molecules29173994

Yao Y, Zhou Y, Liu L, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193. doi:10.3389/fmolb.2020.00193

Hoeben A, Joosten EA, van den Beuken-van Everdingen MH. Personalized medicine: recent progress in cancer therapy. Cancers (Basel). 2021;13(2):242. doi:10.3390/cancers13020242

Salemme V, Centonze G, Avalle L, et al. The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. Front Oncol. 2023;13:1170264. doi:10.3389/fonc.2023.1170264

Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–999. doi:10.1016/j.cell.2017.05.016

Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3. doi:10.1038/s41392-021-00762-6

MacDonald BT, He X. Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. Cold Spring Harb Perspect Biol. 2012;4(12):a007880. doi:10.1101/cshperspect.a007880

Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–1205. doi:10.1016/j.cell.2012.05.012

Stamos JL, Weis WI. The β-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5(1):a007898. doi:10.1101/cshperspect.a007898

Cadigan KM, Waterman ML. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol. 2012;4(11):a007906. doi:10.1101/cshperspect.a007906

Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol. 2009;10(4):276–286. doi:10.1038/nrm2654

Cai WY, Wei TZ, Luo QC, et al. The Wnt-β-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. J Cell Sci. 2013;126(13):2877–2889. doi:10.1242/jcs.123810

Nam Y, Chen C, Gregory RI, et al. Molecular basis for interaction of let-7 microRNAs with Lin28. Cell. 2011;147(5):1080–1091. doi:10.1016/j.cell.2011.10.020

Chen Y, Chen M, Deng K. Blocking the Wnt/β-catenin signaling pathway to treat colorectal cancer: strategies to improve current therapies. Int J Oncol. 2023;62(2):24. doi:10.3892/ijo.2022.5472

Benzing T, Simons M, Walz G. Wnt signaling in polycystic kidney disease. J Am Soc Nephrol. 2007;18(5):1389–1398. doi:10.1681/ASN.2006121355

Post Y, Lu C, Fletcher RB, et al. Design principles and therapeutic applications of novel synthetic WNT signaling agonists. iScience. 2024;27(6):109938. doi:10.1016/j.isci.2024.109938

Xue C, Chu Q, Shi Q, et al. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):106. doi:10.1038/s41392-025-02142-w

Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25(57):7469–7481. doi:10.1038/sj.onc.1210054

Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461–1473. doi:10.1038/onc.2016.304

Zhang Y, Zhang Q, Cao Z, et al. Hoxd3 plays a critical role in breast cancer stemness and drug resistance. Cell Physiol Biochem. 2018;46(4):1737–1747. doi:10.1159/000489249

Lohiya G, Katti DS. A synergistic combination of niclosamide and doxorubicin as an efficacious therapy for all clinical subtypes of breast cancer. Cancers (Basel). 2021;13(13):3299. doi:10.3390/cancers13133299

Zhu G, Gao D, Shao Z, et al. Wnt/β-catenin signaling: causes and treatment targets of drug resistance in colorectal cancer. Mol Med Rep. 2020;23(2):1–9. doi:10.3892/mmr.2020.11744

Yang P, Liu W, Fu R, et al. Cucurbitacin E chemosensitizes colorectal cancer cells via mitigating TFAP4/Wnt/β-catenin signaling. J Agric Food Chem. 2020;68(48):14148–14160. doi:10.1021/acs.jafc.0c05551

Chen B, Zhang D, Kuai J, et al. Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin–ABCG2 signaling pathway in ALDH1+ colorectal cancer stem cells. Tumour Biol. 2017;39(6):101042831771515. doi:10.1177/1010428317715155

Tao H, Chen F, Liu H, et al. Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line. Mol Med Rep. 2017;16(2):1701–1706. doi:10.3892/mmr.2017.6828

Yeung J, Esposito MT, Gandillet A, et al. β-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010;18(6):606–618. doi:10.1016/j.ccr.2010.10.032

Li L, Liu H, Wang C, et al. Overexpression of β-catenin induces cisplatin resistance in oral squamous cell carcinoma. Biomed Res Int. 2016;2016:5378567. doi:10.1155/2016/5378567

Singh R, Reindl KM. Glutathione S-transferases in cancer. Antioxidants (Basel). 2021;10(5):701. doi:10.3390/antiox10050701

Mazari AMA, Zhang L, Ye ZW, et al. The multifaceted role of glutathione S-transferases in health and disease. Biomolecules. 2023;13(4):688. doi:10.3390/biom13040688

Kılıç M., Durmuş İF. Radyodirençlilikte GSTP1 İzoenziminin Olası Rolü: Radyoterapiyle İndüklenen ROS Artışına Yanıt In: KAYA Ö. (ed.) Güncel RADYOLOJİ Çalışmaları IV. Ankara, Akademisyen Kitabevi; 2024 p. 19-30.

Luo W, Kinsey M, Schiffman JD, et al. Glutathione S-transferases in pediatric cancer. Front Oncol. 2011;1:39. doi:10.3389/fonc.2011.00039

Peng X, Zhu J, Liu S, et al. The upregulation of GSTO2 is associated with colon cancer progression and a poor prognosis. J Oncol. 2023;2023:4931650. doi:10.1155/2023/4931650

Dróżdż-Afelt JM, Koim-Puchowska B, Kłosowski G, et al. Polymorphism of glutathione S-transferase in the population of Polish patients with carcinoma of the prostate. Environ Sci Pollut Res Int. 2020;27(16):19375–19382. doi:10.1007/s11356-020-08435-7

Plješa-Ercegovac M, Savić-Radojević A, Matić M, et al. Glutathione transferases: potential targets to overcome chemoresistance in solid tumors. Int J Mol Sci. 2018;19(12):3785. doi:10.3390/ijms19123785

Reis B, Carneiro M, Machado JP, et al. Transcriptional responses of glutathione transferase genes in Ruditapes philippinarum exposed to microcystin-LR. Int J Mol Sci. 2015;16(4):8397–8414. doi:10.3390/ijms16048397

Balabanova D, Remans T, Vassilev A, et al. Possible involvement of glutathione S-transferases in imazamox detoxification in an imidazolinone-resistant sunflower hybrid. J Plant Physiol. 2018;221:62–65. doi:10.1016/j.jplph.2017.12.008

Mian OY, Khattab MH, Hedayati M, et al. GSTP1 loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate. 2015;76(2):199–206. doi:10.1002/pros.23111

He M, Hu J, Fang T, et al. Protein convertase subtilisin/kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway. Cancer Biol Med. 2021;18:0–0. doi:10.20892/j.issn.2095-3941.2020.0313

Mutallip M, Nohata N, Hanazawa T, et al. Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR-133α in head and neck squamous cell carcinoma. Int J Mol Med. 2011;27(3):345–352. doi:10.3892/ijmm.2010.589

Farmohammadi A, Arab-Yarmohammadi V, Ramzanpour R. Association analysis of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer susceptibility. Asian Pac J Cancer Prev. 2020;21(4):1167–1172. doi:10.31557/apjcp.2020.21.4.1167

Louie SM, Grossman E, Crawford LA, et al. GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. Cell Chem Biol. 2016;23(5):567–578. doi:10.1016/j.chembiol.2016.03.017

Sawers L, Ferguson M, Ihrig B, et al. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Br J Cancer. 2014;111(6):1150–1158. doi:10.1038/bjc.2014.386

Song B, Wang L, Zhang Y, et al. Combined detection of HER2, Ki67, and GSTP1 genes on the diagnosis and prognosis of breast cancer. Cancer Biother Radiopharm. 2019;34(2):85–90. doi:10.1089/cbr.2018.2570

Ge J, Tian A, Wang Q, et al. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. PLoS One. 2013;8(6):e67589. doi:10.1371/journal.pone.0067589

Li T, Zhao X, Wang L, et al. Glutathione S-transferase P1 correlated with oxidative stress in hepatocellular carcinoma. Int J Med Sci. 2013;10(6):683–690. doi:10.7150/ijms.5947

Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22(47):7369–7375. doi:10.1038/sj.onc.1206940

Wang H, Zhang L, Hu C, et al. Wnt signaling and tumors. Mol Clin Oncol. 2024;21(1):45. doi:10.3892/mco.2024.2743

Yu F, Yu C, Li F, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6:307. doi:10.1038/s41392-021-00701-5

Zhao X, Ma Y, Luo J, et al. Blocking the WNT/β-catenin pathway in cancer treatment: pharmacological targets and drug therapeutic potential. Heliyon. 2024;10(16):e35989. doi:10.1016/j.heliyon.2024.e35989

Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal. 2018;29(17):1727–1745. doi:10.1089/ars.2017.7342

Zimta AA, Cenariu D, Irimie A, et al. The role of Nrf2 activity in cancer development and progression. Cancers (Basel). 2019;11(11):1755. doi:10.3390/cancers11111755

Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22(47):7369–7375. doi:10.1038/sj.onc.1206940

Wang T, Arifoglu P, Ronai Z, Tew KD. Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem. 2001;276(24):20999–21003. doi:10.1074/jbc.M101355200

Okamura T, Antoun G, Keir ST, et al. Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by epidermal growth factor receptor promotes formation of the GSTP1–JNK complex and suppresses apoptosis in brain tumor cells. J Biol Chem. 2015;290(52):30866–30878. doi:10.1074/jbc.M115.656140

Bartolini D, Stabile AM, Migni A, et al. Subcellular distribution and Nrf2/Keap1-interacting properties of Glutathione S-transferase P in hepatocellular carcinoma. Arch Biochem Biophys. 2024;757:110043. doi:10.1016/j.abb.2024.110043

Li R, Ke M, Qi M, et al. G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway. Exp Hematol Oncol. 2022;11(1):77. doi:10.1186/s40164-022-00326-6

Sun Y, He Q, Li J, et al. A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch. Cell Death Dis. 2023;14(7):463. doi:10.1038/s41419-023-05998-4

Lin W, Wang C, Liu G, et al. SLC7A11/xCT in cancer: biological functions and therapeutic implications. Am J Cancer Res. 2020;10(10):3106–3126.

Zou Y, Zheng S, Xie X, et al. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022;13(1):2672. doi:10.1038/s41467-022-30217-7

Lim JKM, Delaidelli A, Minaker SW, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A. 2019;116(19):9433–9442. doi:10.1073/pnas.1821323116

Wang Y, Zheng L, Shang W, et al. Wnt/β-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ. 2022;29(11):2190–2202. doi:10.1038/s41418-022-01008-w

Yuan S, Tao F, Zhang X, et al. Role of Wnt/β-catenin signaling in the chemoresistance modulation of colorectal cancer. Biomed Res Int. 2020;2020:9390878. doi:10.1155/2020/9390878

Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol. 2006;46:381–410. doi:10.1146/annurev.pharmtox.46.120604.141238

Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650–1653. doi:10.1126/science.1186624

Stein U, Fleuter C, Siegel F, et al. Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells. Br J Cancer. 2012;106(8):1395–1405. doi:10.1038/bjc.2012.81

He K, Gan WJ. Wnt/β-catenin signaling pathway in the development and progression of colorectal cancer. Cancer Manag Res. 2023;15:435–448. doi:10.2147/CMAR.S411168

Vesel M, Rapp J, Feller D, et al. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers and expression is modified by cisplatin via altered Wnt signaling. Respir Res. 2017;18(1):52. doi:10.1186/s12931-017-0537-6

Arend RC, Londoño-Joshi AI, Samant RS, et al. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol Oncol. 2014;134(1):112–120. doi:10.1016/j.ygyno.2014.04.005

Arend RC, Londoño-Joshi AI, Gangrade A, et al. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 2016;7(52):86803–86815. doi:10.18632/oncotarget.13466

Pljesa-Ercegovac M, Savic-Radojevic A, Matic M, et al. Glutathione transferases: potential targets to overcome chemoresistance in solid tumors. Int J Mol Sci. 2018;19(12):3785. doi:10.3390/ijms19123785